Vasculitis: mechanisms involved and clinical manifestations by Guillevin, Loic & Dörner, Thomas
Page 1 of 9
(page number not for citation purposes)
Available online http://arthritis-research.com/content/9/S2/S9
Abstract
Systemic vasculitis, an inflammatory necrotizing disease of the
blood vessel walls, can occur secondary to autoimmune diseases,
including connective tissue diseases. Various pathogenic mecha-
nisms have been implicated in the induction of vasculitis, including
cell-mediated inflammation, immune complex-mediated inflam-
mation and autoantibody-mediated inflammation. This inflammatory
activity is believed to contribute to accelerated atherosclerosis,
and also leads to increased risk for cardiovascular events in
patients with rheumatoid arthritis and systemic lupus erythema-
tosus. Endothelial cell activation is a common pathogenic pathway
in the systemic vasculitis associated with rheumatoid arthritis and
systemic lupus erythematosus, with elevated levels of endothelin-1
potentially inducing vascular dysregulation.
Introduction
The term ‘systemic vasculitis’ describes a heterogeneous
group of rare diseases, the systemic vasculitides, character-
ized by inflammation and fibrinoid necrosis of blood vessel
walls. Vasculitis may be primary in origin (with no identifiable
cause) or it may be secondary to infection, malignancy, or
autoimmune disease. Although rare, there is evidence to
suggest that vasculitis accelerating atherosclerosis is a
complicating feature of most, possibly all, autoimmune
diseases. This includes connective tissue diseases (CTDs)
such as rheumatoid arthritis (RA), scleroderma, sarcoidosis
and systemic lupus erythematosus (SLE).
In this review, which focuses on vasculitis associated with
CTDs, we look at the progress that has been made in
classifying the systemic vasculitides and discuss the patho-
genesis of systemic vasculitides in CTDs and their adverse
clinical sequelae, giving particular attention to RA and SLE.
The standardized treatment for vasculitis is effective in the
majority of patients, but some relapse and need other
therapeutic approaches. In evaluating new treatment
strategies for the management of systemic vasculitis, we
explore the role of endothelin (ET)-1 in systemic vasculitides
and discuss the therapeutic potential of endothelin receptor
blockade in these entities.
Classification of the systemic vasculitides
Early attempts to classify systemic vasculitis into discrete
categories were based primarily on blood vessel size, and
indeed that approach still underpins more recent classifica-
tion schemes. These schemes include those of the American
College of Rheumatology [1] and of the international
consensus conference held in Chapel Hill, North Carolina,
USA that gave rise to the Chapel Hill nomenclature [2].
Today, most physicians use the Chapel Hill nomenclature,
which is based on clinical and histopathological features of
vasculitis (Figure 1).
In essence, classification schemes, including the Chapel Hill
nomenclature, recognize two major groups of systemic
vasculitides [2]: large vessel vasculitis, which consists of
giant cell arteritis (GCA) and Takayasu arteritis, both of which
involve the aorta and its major branches; and necrotizing
vasculitis, which encompasses the rest of the vasculitides.
The necrotizing systemic vasculitides include polyarteritis
nodosa and Kawaski disease, which affect medium-sized
arteries, and a large group of disorders in which the vasculitis
affects arterioles, capillaries and venules (Figure 1). Within
this latter group there are four disorders, namely Wegener’s
granulomatosis, Churg-Strauss syndrome, microscopic
polyangiitis and necrotizing glomerulonephritis, which are
characterized by the presence of anti-neutrophil cytoplasmic
antibodies (ANCAs). Other types of small vessel vasculitis
include Henoch-Schönlein purpura, which is characterized by
IgA-dominant immune deposits in the small blood vessels,
and essential cryoglobulinaemic vasculitis, in which
cryoglobulin immune deposits are responsible for small blood
vessel vasculitis (Figure 1).
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The vasculitides that occur in autoimmune diseases usually
affect small-sized vessels, as is the case in SLE, systemic
sclerosis and Sjögren’s syndrome. Where vasculitis occurs
during the course of RA, the small arteries are involved in
most patients but medium-sized arteries can also be affected,
mimicking polyarteritis nodosa. A comprehensive overview of
the classification of systemic vasculitides was recently
reported by Sunderkötter and Sindrilaru [3].
Pathogenesis of vasculitis
Progress in the classification of the systemic vasculitides has
facilitated better understanding of the pathogenesis under-
lying these inflammatory conditions, which can involve cell-
mediated inflammation, immune complex (IC)-mediated inflam-
mation, and ANCA-mediated inflammation. Of central
importance is that many data have accumulated demon-
strating that various inflammatory pathways lead to endothelial
cell activation, which may induce complications such as vessel
occlusion and tissue destruction in a predisposed host, and
longstanding disease. Investigations into ANCA vasculitides
have pioneered the field and expanded our understanding of
the pathogenesis of vessel inflammation. Comprehensive
overviews of the pathogenic mechanisms that underlie the
vasculitides and the distinction between primary and
secondary vasculitis were published elsewhere [3,4].
In GCA, for example, vasculitis is essentially a T-cell driven
process that is triggered by exposure to antigens, most
probably infectious agents. Dendritic cells present in the
adventitia and media of the blood vessel wall are potent
antigen-presenting cells that can prime naïve T cells. In
patients with GCA they are responsible for activating CD4+
T cells, which orchestrate vascular injury by recruiting macro-
phages and monocytes to the vessel walls [5]. These cells
induce systemic inflammation via the release of cytokines,
such as interleukin-1 and interleukin-6. Tissue resident T cells
also release interferon-γ, which is a key proinflammatory
cytokine that has been implicated in the pathogenesis of
GCA. Sustained inflammation mediated by T cells, macro-
phages and the proinflammatory cytokines released by these
cells leads to extensive intimal thickening and vessel
occlusion (Figure 2). Platelet-derived growth factor and
vascular endothelial growth factor play key roles in the subse-
quent development of the lumen-occlusive arteritis that
characterizes GCA.
In contrast to GCA, which appears to be an antigen-driven
disease with local T cell and macrophage activation in the
vessel wall, IC formation is usually considered to be the major
pathological event in polyarteritis nodosa, cryoglobulinaemia
and Henoch-Schönlein purpura. In polyarteritis nodosa, for
example, antibody-mediated IC deposition can lead to renal
infarction. Micro-aneurisms are another manifestation that can
occur as a consequence of IC formation in the medium-sized
necrotizing systemic vasculitides, which can also lead to
blood vessel occlusion. However, this is mediated to a large
extent by circulating antibodies in blood and antibody-
dependent effector mechanisms rather than as a result of
cell-mediated inflammation. With regard to IC-mediated
vascular damage, it has been demonstrated in CD18-/- mice
that ICs induce damage from the luminal side but not from
perivascular areas. Therefore, in this entity it has been
suggested that the interaction of ICs, Fcγ receptors and
adhesion molecules leads to disturbances in transmigration
and activation of polymorphonuclear neutrophils, with
consequent vessel damage [6].
Autoantibodies play a central role in the ANCA-related
vasculitis that is characteristic of Wegener’s granulomatosis,
Churg-Strauss syndrome, microscopic polyangiitis and
necrotizing glomerulonephritis. These antibodies are directed
against enzymes that are contained in the granules of
neutrophils and monocytes. In Wegener’s granulomatosis
they primarily target proteinase 3, which is a neutral serine
protease, and - in microscopic polyangiitis and Churg-Strauss
syndrome - they target myeloperoxidase, which is an enzyme
that is involved in the generation of reactive oxygen species.
Both proteinase 3-ANCA and myeloperoxidase-ANCA can
contribute to vasculitis in the small blood vessels, causing
adverse clinical sequelae such as pauci-immune glomerulo-
nephritis and pulmonary haemorrhage, as demonstrated in
animal models (myeloperoxidase) [7]. An enhancing effect of
ANCAs on leucocyte diapedesis caused by their interaction
with the endothelium was recently demonstrated in a study
involving passive transfer of immunoglobulin [8]; this proce-
dure resulted in microvascular haemorrhage.
Vasculitis in autoimmune diseases
Vasculitis may occur in many autoimmune diseases, including
RA and SLE (which are the focus of this review), Sjögren’s
syndrome, scleroderma and sarcoidosis. Primary Sjögren’s
Figure 1
Classification of the systemic vasculitis. Reproduced with permission
from Jennette et al. Arthritis Rheum 1994 © John Wiley &
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syndrome is associated with enhanced risk for B-cell
lymphoma [9], in which the presence of purpura or vasculitis
are clinical risk indicators for future non-Hodgkin’s lymphoma
development, as has been identified in a number of studies
primarily based on epidemiological data [10]. In association
with SLE, for example, distinctive characteristics of coexistent
vasculitis include the presence of anti-Ro-SSA, HLA and DR3
antibodies, as well as (more rarely) anti-DNA, anti-Sm and
anti-RNP antibodies. Clinical presentation can include
purpura, peripheral neuropathy of the lower limbs, and
hypergammaglobulinaemia. Many patients will also exhibit
evidence of rheumatoid factor activity, cryoglobulinaemia due
to monoclonal IgM (kappa) paraprotein, and low complement
levels. Pulmonary involvement is uncommon in vasculitis
associated with Sjögren’s syndrome, although patients may
develop interstitial lung disease, pulmonary hypertension, or
lymphocytic interstitial pneumonia. Mesenteric vasculitis and
biliary cirrhosis are seen in cases with gastrointestinal tract
involvement, whereas cognitive dysfunction, infarcts and
neuropsychiatric symptoms may indicate central nervous
system involvement. Renal involvement is less common in
vasculitis related to Sjögren’s syndrome, but when it does
occur it usually manifests as interstitial nephritis. Vasculitis is
extremely rare in scleroderma. If present, it is usually seen in
the small blood vessels, sometimes in association with
ANCA-related vasculitis. Vasculitis is also rare in sarcoidosis.
It may affect the skin as leucocytoclastic granulomatosis
often in association with sarcoid necrotizing granulomatosis
[11]. It may also occur as synovial vasculitis. Very rarely, the
aorta, pulmonary artery and mesenteric arteries are affected,
giving rise to a very severe form of large-vessel vasculitis that
mimics Takayasu arteritis. Patients with this form of vasculitis
develop aortitis with stenoses, aneurisms and dissection, and
have a poor prognosis.
Atherosclerosis appears to be accelerated in patients with
vasculitis, although it is difficult to discern its contributing impact
on subsequent vascular occlusion. Moreover, corticosteroids,
which are required for the treatment of inflammatory diseases
such as RA, chronic obstructive pulmonary disease and inflam-
matory bowel disease, may also enhance risk for cardiovascular
complications, as was recently demonstrated [12].
Vasculitis in rheumatoid arthritis and
systemic lupus erythematosus
Vasculitis is a known complication of RA, often occurring
several years after the initial onset of disease. Observational
studies have shown that, independent of sex, patients with
RA have reduced life expectancy in comparison with the non-
RA population [13]. Rheumatoid vasculitis is characterized by
the occurrence of mononeuritis multiplex, purpura and
visceral involvement, with the latter sometimes being severe.
This vasculitis is severe and, in its systemic form, should
usually be treated with corticosteroids and cyclophos-
phamide. Despite such treatment, the outcome is worse than
with the majority of vasculitides [14].
In addition to this severe inflammatory disease, patients with
RA appear to be at significantly increased risk from coronary
events in comparison with healthy individuals [15]. Obser-
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Figure 2
Pathogenesis of giant cell arteritis. (a) Recruitment and stimulation of antigen-specific T cells by dendritic cells. Interferon-γ regulates the differentiation
and function of macrophages. Macrophages in the adventitial layer supply interleukin-1 and interleukin-6, and in the media secrete metalloproteinases.
(b) Platelet-derived growth factor and vascular endothelial growth factor are responsible for intimal hyperplasia, then favour lumen-occlusive arteritis.
Reproduced with permission from Weyland et al. N Engl J Med 2003 Copyright © 2003 Massachusetts Medical Society [5].vational studies have shown that, compared with healthy
normal individuals, patients with RA are at double the risk for
developing coronary artery disease [16,17], as reflected by
unrecognized myocardial infarction, as well as congestive
heart failure [18] and sudden cardiac death [16] (Figure 3). A
recent study that sought to identify demographic and
cardiovascular risk factors in RA patients with and without
atherosclerotic plaque in the carotid arteries [19]
demonstrated that age, hypertension (especially raised
systolic blood pressure), raised cholesterol, raised low-
density lipoprotein levels and (to a lesser extent) homo-
cysteinaemia were the factors that differed most significantly
between the two patient populations.
As data from these and other observational studies have
illustrated, RA patients are at significantly increased risk for
developing cardiovascular disease relative to the normal
population. Studies have also shown that inflammation is a
key link between RA and accelerated atherosclerosis.
Correlations have been demonstrated between intima-media
thickness (a surrogate marker for cardiovascular disease) and
measures of inflammation such as erythrocyte sedimentation
rate and C-reactive protein [20]. It has also been suggested
that corticosteroids may facilitate atherosclerosis [21].
The picture in SLE is similar to that in RA, except that patients
with SLE exhibit an even greater incidence of atherosclerotic
plaque in carotid arteries [22,23], a higher rate of calcification
in the coronary arteries [24], and a correspondingly higher
frequency of myocardial infarction and stroke when compared
with the normal population. It should be noted that patients
with SLE and antiphospholipid syndrome, but also those with
subacute cutaneous lupus erythematosus, frequently present
with a livedo vasculopathy. This is of particular interest
because it reflects a certain type of small-vessel vasculitis.
However, in patients with antiphospholipid syndrome that is
independent of any underlying disease, livedo may be present
in the absence of other signs or findings of vasculitis.
Although risk factors for atherosclerosis in SLE patients are
similar to those in patients with RA, there are additional SLE-
related risk factors (Figure 4). These include the development
of autoantibodies to endothelium, high-density lipoprotein and
phospholipids, as well as dyslipidaemia [22]. The enhanced
frequency of circulating ICs, activated complement products
and nephritis are additional SLE-related risk factors [25].
These additional risk factors may explain why SLE patients
are at greatly increased cardiovascular risk, even relative to
that in patients with RA. Certainly, SLE carries a risk for
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Figure 3
Data showing increased cardiovascular risk in patients with RA versus the normal population. MI, myocardial infarction; RA, rheumatoid arthritis.
Reproduced with permission from Nicola et al. Arthritis Rheum 2005 and Maradit-Kremers et al. Arthritis Rheum 2005 © John Wiley &
Sons/American College of Rheumatology [16,18].accelerated atherosclerosis that is greater than the net sum
of classical risk factors [26]. Whether accelerated
atherosclerosis in SLE is uniquely related to inflammatory
activity or to additional factors, or both, remains uncertain. By
unravelling the pathogenic mechanisms that are responsible
for the vasculitis that occurs in RA and SLE, as well as the
interaction of inflammation and procoagulatory mechanisms,
we may develop a greater understanding of the contribution
of vasculitis to adverse cardiovascular outcomes in these and
other CTDs.
Pathogenic mechanisms of vasculitis in
rheumatoid arthritis and systemic lupus
erythematosus
Autoantibodies
In autoimmune diseases such as RA and SLE there is
evidence of an absolute deficiency in the CD4+ T-cell popula-
tion, a decreased CD4/CD8 ratio and, most importantly, a
diminished relative percentage of CD4+CD25+ regulatory
T cells. There is also abundant evidence for induction of
autoantibodies, including anti-endothelial cell antibodies
(AECAs), antibodies against adhesion molecules on the
endothelial cell surface, and antibodies against induced auto-
antigens on the surface of endothelial cells [27,28]. Although
AECAs are a focus of debate and may represent an
epiphenomenon, these autoantibodies are thought to activate
endothelial cells, leading to (among other things) upregulation
of adhesion molecules (intercellular adhesion molecule-1,
endothelial leucocyte adhesion molecule-1 and vascular cell
adhesion molecule-1) and other major histocompatibility class
II molecules [29,30]. In the presence of natural killer cells
they may trigger endothelial cell apoptosis [31] or lead to the
induction of effector mechanisms via antibody-dependent
cellular cytotoxicity and complement activation [32,33]. Of
importance, endothelial cells play a crucial role in inflam-
mation and coagulation. A number of heterogeneous factors
(antibodies by binding with the variable region to expressed
antigens or by their constant region via Fc receptors, ligation
of Toll-like receptors on the endothelial cell surface, as well
as transmembranous migrating low-density lipoprotein trans
fatty acids) can lead to nuclear factor-κB dependent endo-
thelial cell activation (Figure 5). As a result, the endothelial
cell achieves a procoagulatory status, which is not obviously
dependent on the initial insult.
Studies in patients with SLE have revealed that as many as
80% of patients produce AECAs, which are heterogeneous
antibodies that react with various endothelial antigens. In SLE
these antigens include constitutive heparin-like molecules (25
to 200 kDa) and nuclear antigens, of which heat shock
protein 60 and the autoantigens Ro(SS-A) and La(SS-B) are
the best characterized. These autoantigens can either be
expressed on the surface after intracellular translocation or
they can adhere to the surface of endothelial cells after
release, where they can be recognized by cognate auto-
antibodies. AECAs are also present in patients with RA and
especially in those who present with clinical vasculitis, in
which the presence of AECAs correlates with extra-articular
manifestations of the disease [34,35].
IC formation and binding to the endothelial cell surface
leading to endothelial cell activation plays an important role in
the pathogenesis of vasculitis and is a feature of vasculitis in
both RA and SLE [35]. In these diseases, ICs can activate
endothelial cells simply by binding to Fcγ receptors. This
leads to plasma extravasation, recruitment of leucocytes to
the perivascular environment, an enhanced inflammatory
response from endothelial paracrine mediators and, finally,
activation of the coagulation system and development of a
prothrombotic state [6,36].
Fcγ receptor binding on endothelial cells is also a critical
process after binding of specific autoantibodies to blood
cells (for example, ANCA binding to neutrophils) because it
initiates binding to the target tissue and subsequent
destruction, such as that seen in vasculitis.
Additional processes are involved, such as activation of
endothelial cells by shear stress, binding of von Willebrand
factor, regulation of ET-1, thrombomodulin and thrombin
receptor, adhesion molecules and activation of thrombocytes,
the sequence of which is beginning to be understood. Thus,
release of these factors leads to increased levels in serum
and cannot be considered a primary pathogenic event in
vasculitis, whereas, for example, enhanced ET-1 levels in
scleroderma and Raynaud’s have pathogenic relevance.
Available online http://arthritis-research.com/content/9/S2/S9
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Figure 4
Enhanced cardiovascular risk in SLE and SLE-related risk factors.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SLE,
systemic lupus erythematosus. Reproduced with permission from
Nicola et al. N Engl J Med 2003 Copyright © 2003 Massachusetts
Medical Society [18].Role of endothelin in vasculitides
Binding of autoantibodies and ICs to the surface of endothelial
cells results, among other things, in enhanced ET-1 release.
ET-1 is known to activate monocytes via activation of the
endothelin receptor subtype A [37] and to contribute to matrix
remodelling [38]. Raised levels of ET-1 have been described
in both RA and SLE patients. Pache and colleagues [39], for
example, reported significantly elevated plasma levels of ET-1
in RA patients as compared with control individuals, and
suggested that they might be related to vascular
dysregulation, as observed in nail-fold capillaroscopy. Raised
plasma concentrations of ET-1 have also been described in
SLE patients [39]. Again, there is a suggestion that elevated
ET-1 may act as a marker of vascular damage [40,41]. There
are clear data that ET-1 is enhanced in SLE patients with
pulmonary arterial hypertension [42], and usage of the dual
endothelin receptor antagonist bosentan resulted in clinical
improvements in this subset of patients [43].
Albeit few, there are reports of increased ET-1 in the acute
phase of Henoch-Schönlein purpura, with levels returning to
normal during remission [44]. Raised levels of ET-1 have also
been described in the early stages of GCA and may
contribute to the vascular occlusion seen in some patients
[45]. Macrophages are known to produce matrix metallo-
proteinase-2, which is an analogue of endothelin-converting
enzyme that cleaves big ET-1 to ET-1; this could account for
the high levels of ET-1 seen in the early stage of GCA.
Therapeutic strategies: the potential of
endothelin blockade
Immunosuppression
Clinical management of vasculitis associated with CTDs
requires a multipronged approach, addressing the underlying
disease and its severity as well as the vasculitis itself.
Additionally, there may be a need to treat symptomatic
manifestations of the disease. Overall, the aim of treatment is
to control disease, prevent relapse and increase event-free
survival. Preliminary clinical data in RA indicate that
controlling disease activity by methotrexate reduces fatal
acute myocardial infarction [46] and tumour necrosis factor
therapy is able to improve endothelial function [47].
Currently, corticosteroids and immunosuppressants such as
cyclophosphamide are the mainstay of treatment for
vasculitis. Other drugs such as bisphosphonates and co-
trimoxazole may be included as adjunctive treatments. The
therapeutic regimen should be carefully chosen and, in cases
of primary vasculitis, tailored according to criteria that
constitute a five-point prognostic score: proteinuria
(>1 g/day), raised creatinine levels (>140 µmol/l), gastro-
intestinal tract involvement, specific cardiomyopathy and
central nervous system involvement. A study examining this
scoring system, which has been validated in polyarteritis
nodosa, microscopic polyangiitis and Churg-Strauss
syndrome, showed that patients fulfilling none of the criteria
have only a 12% mortality at 5 years as compared with 50%
mortality in those satisfying two of the criteria [48].
A common approach to treatment, and one supported by
data from the European Vasculitis Study Group on ANCA-
associated vasculitis and Wegener’s granulomatosis, is to
use short-term cyclophosphamide over a 3-month to 6-month
period as induction therapy, and then to switch patients to
maintenance therapy with either azathioprine or methotrexate
(Figure 6). This is in addition to background corticosteroid
therapy [49]. This strategy has also proved effective in
vasculitis secondary to RA; patients initially received short-
Arthritis Research & Therapy    Vol 9 Suppl 2 Guillevin and Dörner
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Figure 5
Pathways leading to nuclear factor-κB dependent endothelial cell activation. Ab, antibody; IC, immune complex; JNK, c-Jun amino-terminal kinase;
LDL, low-density lipoprotein; MAPK, mitogen-activated protein kinase; MyD88, myeloid differentiation primary response gene 88; NF-κB, nuclear
factor-κB; PAI, plasminogen activator inhibitor; ROS, reactive oxygen species; TLR, Toll-like receptor; TM, thrombomodulin; TR, thrombin receptor.
Reprinted from Iba et al.: The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg 1998; 187(3):321–329. 
© 1998 by the American College of Surgeons, with permission from Elsevier [36].course pulsed cyclophosphamide and were then switched to
an alternate immunosuppressant agent. In our experience,
azathioprine and methotrexate are equally effective in main-
taining remission; for induction, cyclophosphamide remains
the best treatment at present.
Biological therapies
The advent of biological immunomodulatory therapies, such as
rituximab and infliximab, has potentially increased therapeutic
options in systemic vasculitis. Promising results for anti-CD20
therapy with rituximab have been described in patients with
Wegener’s granulomatosis and ANCA-associated vasculitis,
including refractory ANCA vasculitis [50,51]. In a small, open-
label study [51], treatment with rituximab depleted circulating
B cells while also suppressing ANCA antibody titres and
inducing longstanding remission. Treatment of necrotizing
vasculitides, such as Wegener’s granulomatosis, with the anti-
tumour necrosis factor-α agent infliximab has also shown early
promise. Encouragingly, efficacy was seen in patients who
were unresponsive to standard therapies, rituximab and
intravenous immune globulin.
The potential for endothelin-1 blockade
Although data are limited, there is evidence suggesting that
ET-1 plays some role in the clinical manifestations of
vasculitis; blockade of ET-1 could therefore be of therapeutic
benefit, albeit probably as add-on therapy. From a clinical
perspective, there is a lack of longitudinal data on ET-1 levels
in relation to disease activity and of ET-1 levels in response to
standard therapies. It is also unclear whether elevated ET-1 is
a risk factor for cardiovascular complications in CTDs,
although it undoubtedly is for pulmonary arterial hypertension.
ET-1 antagonism with drugs such as bosentan is an
established treatment for pulmonary arterial hypertension. In
addition to its established indications, it is possible that drugs
such as bosentan might be helpful in specific vascular
manifestations, such as renal vasculitis, ischaemia, and
ischaemia complicating severe Raynaud’s phenomenon.
Recently bosentan was approved in Europe to reduce the
number of new digital ulcers in patients with SSc and
ongoing digital ulcer disease.
Conclusion
Systemic vasculitis is characterized by multiple phenotypes
that reflect the different pathogenic mechanisms that are
responsible for inducing inflammation in the large, medium
and small blood vessels (arterioles, venules and capillaries) of
the body’s tissues and organs. Although cell-mediated inflam-
mation is characteristic of GCA, a systemic vasculitis of the
large blood vessels, IC-mediated inflammation and ANCA-
mediated inflammation are seen in the necrotizing vasculi-
tides that affect medium-sized and small blood vessels.
Systemic vasculitis, a rare complication of autoimmune
disorders, can nevertheless occur in most if not all CTDs.
Evidence suggests that inflammation is a key link between
vasculitis and accelerated atherosclerosis in these patients.
Certainly, patients with RA and SLE are at significantly
increased risk for cardiovascular morbidity and mortality in
comparison with the normal population. Although preliminary
data point to effects of immunosuppression on cardiovascular
complications, this must be substantiated. There is a clear
need for prevention studies (lipid and blood pressure control)
in conjunction with control of disease activity, which requires
delineation of the factors that drive vasculitis and endothelial
cell activation.
Endothelial cell activation via autoantibody or IC binding is a
common pathogenic pathway in systemic vasculitis
associated with RA and SLE, superimposing on ‘baseline
risks’ (blood pressure, Toll-like receptor ligands, enhanced
low-density lipoproteins and smoking), leading among other
things to enhanced release of ET-1. There is evidence, albeit
limited, suggesting that ET-1 plays a role in some clinical
manifestations of vasculitis. Potentially, endothelin receptor
antagonism may have a place in the treatment of specific
vascular manifestations of vasculitis as an adjunct to standard
therapy with corticosteroids and immunosuppressant agents.
Effective ET-1 blockade has been demonstrated in SLE
patients with pulmonary arterial hypertension.
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